P17.22 LOMUSTIN OR BEVACIZUMAB AT FIRST RECURRENCE OF GLIOBLASTOMA

Por Clement, P.M., Caenepeel, C., Beuselinck, B., Bechter, O.E.
Publicado em 2014

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

Por Beuselinck, B, Wolter, P, Karadimou, A, Elaidi, R, Dumez, H, Rogiers, A, Van Cann, T, Willems, L, Body, J-J, Berkers, J, Van Poppel, H, Lerut, E, Debruyne, P, Paridaens, R, Schöffski, P
Publicado em 2012

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

Por Bamias, A, Tzannis, K, Beuselinck, B, Oudard, S, Escudier, B, Diosynopoulos, D, Papazisis, K, Lang, H, Wolter, P, de Guillebon, E, Stravodimos, K, Chrisofos, M, Fountzilas, G, Elaidi, R-T, Dimopoulos, M A, Bamia, C
Publicado em 2013

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs

Por Beuselinck, B, Jean-Baptiste, J, Couchy, G, Job, S, De Reynies, A, Wolter, P, Théodore, C, Gravis, G, Rousseau, B, Albiges, L, Joniau, S, Verkarre, V, Lerut, E, Patard, J J, Schöffski, P, Méjean, A, Elaidi, R, Oudard, S, Zucman-Rossi, J
Publicado no Br J Cancer (2015)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

Por Beuselinck, B, Karadimou, A, Lambrechts, D, Claes, B, Wolter, P, Couchy, G, Berkers, J, Paridaens, R, Schöffski, P, Méjean, A, Verkarre, V, Lerut, E, de la Taille, A, Tourani, J-M, Bigot, P, Linassier, C, Négrier, S, Berger, J, Patard, J-J, Zucman-Rossi, J, Oudard, S
Publicado em 2013